Kenyans Advised Against Using Popular Drug

The Pharmacy and Poisons Board (PPB) has issued a critical recall of S-Prazo (Esomeprazole Magnesium Delayed-Release Capsules 40mg), specifically Batch No. SPZ-302, due to a serious mix-up in packaging. Esomeprazole is a widely used medication for treating conditions like heartburn, gastroesophageal reflux disease (GERD), and stomach ulcers. However, the PPB discovered that some boxes of the affected batch contained blister strips for both S-Prazo Capsules and Donystatin tablets, a completely different medication, within the same carton.

This alarming discovery has led the PPB to take immediate action. All pharmaceutical outlets, healthcare facilities, and professionals, as well as the general public, have been directed to halt the distribution, sale, and use of the affected batch. Kenyans who have purchased this medication are advised to return the drugs to the nearest healthcare facility or their respective suppliers to prevent any potential health risks.

The PPB has emphasized its commitment to safeguarding public health against substandard and potentially dangerous drugs. They have urged the public to report any cases of substandard drugs or adverse drug reactions promptly, either to the nearest healthcare facility or directly to the Pharmacy and Poisons Board.

This recall comes on the heels of another significant health alert from just five months ago, when the government warned against the purchase of Benylin Pediatric 100ml cough syrup, specifically Batch No. 329304. This product, manufactured in South Africa, was recalled after Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) raised concerns.

The PPB’s actions underscore the importance of vigilance in the pharmaceutical industry and the need for ongoing efforts to ensure that all medications available to the public meet safety and quality standards. For those relying on these medications, this recall serves as a reminder to always stay informed and take precautions when dealing with potentially compromised drugs.